Analysis of peripheral tolerance in vivo
体内外周耐受性分析
基本信息
- 批准号:8308579
- 负责人:
- 金额:$ 33.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2013-05-14
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdoptive TransferAffinityAntigen-Presenting CellsAntigensAutoantigensAutoimmune DiseasesAutoimmunityCD4 Positive T LymphocytesCell DeathCellsComplexDevelopmentEctopic ExpressionEpithelial CellsEventFemaleGene TargetingGoalsIndividualInflammationLeadLigandsLightLymphoidLymphokinesMagnetismMajor Histocompatibility ComplexMature T-LymphocyteMediatingMethodsModelingMusOrganPeptidesPeripheralPhenotypePhysiologicalPlayPregnancyPrincipal InvestigatorProcessProductionProliferatingProteinsRegulatory T-LymphocyteRoleSeriesSurvivorsT cell anergyT-Cell ReceptorT-LymphocyteTestingThymus GlandTissuesTransgenic Micebasefunctional statusimmunogenicin vivomemberperipheral tolerancepregnantprogramsreceptorresearch studysperm cellsuccesstheoriesthymocytetooltranscription factor
项目摘要
The long-term goal of this project is an understanding of the mechanisms that account for CD4+ T cell
tolerance to antigens that are presented in the secondary lymphoid organs but not the thymus. Previously, we
showed that naive CD4+ T cells that are exposed to model antigens in the secondary lymphoid organs in the
absence of inflammation proliferate poorly, then most of the progeny die, and the survivors enter an anergic
state characterized by poor lymphokine production. The goal of this application is to establish whether or not
a similar series of events accounts for peripheral tolerance to certain natural self-proteins. This has become a
pressing issue since the discovery that the AIRE transcription factor drives ectopic expression of extrathymic
gene products in the thymus. Thus, it remains possible that the physiological role that peripheral tolerance
was thought to play is really played by AIRE-mediated intrathymic tolerance. Here, we will test the hypothesis
that peripheral tolerance is physiologically-relevant by using new tools to identify the tolerance mechanisms
that apply to two pregnancy-specific proteins, one that appears to be regulated by AIRE and another that
does not, and one sperm-specific protein. We will determine whether or not these proteins are immunogenic
in mice that have never expressed them in the relevant tissue (e.g., non-pregnant female mice), and become
non-immunogenic in mice after expression (e.g., pregnant female mice). The relevant antigenic peptides will
be identified and used to produce peptide-MHC II multimers. The multimers will then be used with a sensitive
new enrichment method capable of detecting fewer than 100 cells per mouse to enumerate peptide MHC II-
specific CD4+ T cells before, during, and after expression of the relevant protein within the polyclonal
repertoires of normal mice. This approach should reveal whether or not the relevant CD4+ T cells are deleted,
turn into regulatory cells, or become anergic during or after the period when these developmental^ regulated
self-proteins are expressed. This approach will then be used in gene-targeted mice to determine whether or
not molecules such as Fas and Cbl-b, and others identified by other members of the P01, are involved in the
identified tolerance mechanism. Success would provide the first definitive identification of the peripheral
tolerance mechanism that applies to a natural self-antigen. This information should help focus future research
on the relevant mechanism and shed light on the potential ways that it could fail and lead to autoimmunity.
该项目的长期目标是了解CD 4 + T细胞的机制,
对次级淋巴器官而不是胸腺中呈递的抗原的耐受性。此前我们
显示在小鼠的次级淋巴器官中暴露于模型抗原的幼稚CD 4 + T细胞在小鼠的次级淋巴器官中表达。
如果没有炎症,则增殖不良,然后大多数后代死亡,幸存者进入无反应性阶段。
以淋巴因子产生不足为特征的状态。本申请的目的是确定是否
类似的一系列事件解释了外周对某些天然自身蛋白的耐受性。这已经成为一个
这是一个紧迫的问题,因为发现AIRE转录因子驱动胸腺外
胸腺中的基因产物。因此,外周耐受性的生理作用仍然是可能的
实际上是由AIRE介导的胸腺内耐受发挥作用。在这里,我们将测试假设
通过使用新的工具来识别耐受机制,
这适用于两种妊娠特异性蛋白质,一种似乎受AIRE调节,另一种
没有,还有一种精子特异性蛋白质。我们将确定这些蛋白质是否具有免疫原性
在从未在相关组织中表达它们的小鼠中(例如,非妊娠雌性小鼠),并成为
表达后在小鼠中无免疫原性(例如,怀孕的雌性小鼠)。相关的抗原肽将
鉴定并用于产生肽-MHC II多聚体。然后将多聚体与敏感的
一种新的富集方法,能够检测每只小鼠少于100个细胞,以计数肽MHC II-
特异性CD 4 + T细胞在多克隆抗体内表达相关蛋白之前、期间和之后的表达。
正常小鼠的所有基因组。这种方法应该揭示相关的CD 4 + T细胞是否被删除,
在这些发育受调节的时期或之后,
自身蛋白表达。然后将这种方法用于基因靶向小鼠,以确定是否或
而Fas和Cbl-b等分子以及P01的其他成员所鉴定的其他分子则不参与细胞凋亡。
确定了容忍机制。成功将提供第一个明确的识别外围设备
耐受机制适用于天然自身抗原。这些信息应该有助于集中未来的研究
相关机制,并阐明其可能失败并导致自身免疫的潜在方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc Kevin Jenkins其他文献
Marc Kevin Jenkins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc Kevin Jenkins', 18)}}的其他基金
Detection and Activation of CD4+ T cells with Low Affinity TCRs
低亲和力 TCR 的 CD4 T 细胞的检测和激活
- 批准号:
10348758 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
Detection and Activation of CD4+ T cells with Low Affinity TCRs
低亲和力 TCR 的 CD4 T 细胞的检测和激活
- 批准号:
10570243 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 33.06万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 33.06万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 33.06万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 33.06万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 33.06万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 33.06万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 33.06万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 33.06万 - 项目类别: